DS
TRDA icon

David Shaw’s Entrada Therapeutics TRDA Stock Holding History

David Shaw’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Sell
32,397
-46,650
-59% -$447K ﹤0.01% 4503
2026
Q1 		$998K Buy
79,047
+12,169
+18% +$139K ﹤0.01% 3452
2025
Q4 		$688K Sell
66,878
-4,670
-7% -$39.4K ﹤0.01% 3761
2025
Q3 		$415K Buy
+71,548
New +$419K ﹤0.01% 3954

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

David Shaw's TRDA Position: Q2 2026 in Review

David Shaw reduced its Entrada Therapeutics (TRDA) stake by 59% in Q2 2026, selling an estimated $447K and leaving 32,397 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #4503.

David Shaw first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $998K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • David Shaw held 32,397 shares of Entrada Therapeutics worth $238K as of Q2 2026.
  • David Shaw sold 46,650 Entrada Therapeutics shares in Q2 2026, an estimated $447K.
  • Entrada Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4503 holding.
  • David Shaw first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • David Shaw's Entrada Therapeutics position peaked at $998K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.